Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Payables (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Payables for 16 consecutive years, with $792483.0 as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 61.39% to $792483.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $792483.0, a 61.39% decrease, with the full-year FY2025 number at $792483.0, down 61.39% from a year prior.
  • Payables was $792483.0 for Q4 2025 at Cryo Cell International, down from $2.8 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $9.6 million in Q3 2022 to a low of $601564.0 in Q4 2022.
  • A 5-year average of $3.0 million and a median of $2.9 million in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: plummeted 74.12% in 2022, then soared 455.26% in 2023.
  • Cryo Cell International's Payables stood at $2.3 million in 2021, then tumbled by 74.12% to $601564.0 in 2022, then skyrocketed by 455.26% to $3.3 million in 2023, then tumbled by 38.54% to $2.1 million in 2024, then tumbled by 61.39% to $792483.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Payables are $792483.0 (Q4 2025), $2.8 million (Q3 2025), and $2.4 million (Q2 2025).